Uterine sarcoma, usually leiomyosarcoma, is commoner among women operated on for presumed fibroids than has been assumed — current data put the risk as high as about one in 770. The consequence of missing it is specific and severe: minimally invasive treatment of an unsuspected leiomyosarcoma can delay definitive therapy or disseminate disease within the peritoneum.
The imaging tools are available and perform well. Contrast-enhanced MRI with diffusion-weighted imaging and apparent diffusion coefficient measurement gives reported accuracy of 88% to 94.6% for detecting uterine leiomyosarcoma. The Radiology 2023 consensus statement on MRI evaluation of uterine masses for leiomyosarcoma risk provides the algorithm, which has been preliminarily validated, and this review adds practical nuance to applying it.
What changes is where the radiologist sits in the pathway. A woman going for hysterectomy or myomectomy for symptomatic fibroids is often imaged by ultrasound alone, and the sarcoma question is never formally asked. Recasting the report as a risk assessment — stating explicitly whether features of leiomyosarcoma are present or absent, and recommending contrast-enhanced MRI with diffusion-weighted sequences where the question is open — is what makes the accuracy figures usable rather than theoretical.
That matters more where morcellation and minimally invasive fibroid surgery are common and preoperative MRI is not routine, which describes much of Indian practice. The realistic intervention is not to MRI every fibroid; it is to make sure the surgical team has an answer to the sarcoma question, one way or the other, before a mass is morcellated.
- State explicitly in the report whether features of leiomyosarcoma are present or absent when reporting a uterine mass before planned surgery
- Recommend contrast-enhanced MRI with diffusion-weighted imaging and apparent diffusion coefficient measurement where the sarcoma question is open
- Raise the sarcoma question specifically before any planned morcellation or minimally invasive fibroid surgery
- Use the published consensus algorithm rather than an individual impression of what looks worrying
- Quote the accuracy as 88% to 94.6% — good, but not a rule-out at an individual patient level
Why it matters
A fibroid that is morcellated is a decision made on imaging that was never asked to answer the question.
Don't overread it
At this prevalence a positive MRI is far more often a false alarm than a sarcoma, so it should trigger discussion of surgical approach rather than a diagnosis.
The statistics, in plain English
A reported accuracy range of 88% to 94.6% comes from studies with different populations and reference standards, so it is a range of estimates rather than a confidence interval. Accuracy also depends heavily on how common sarcoma is in the group imaged: at a prevalence near one in 770, even a highly accurate test produces far more false positives than true ones, so a positive MRI raises suspicion rather than establishing a diagnosis. The consensus algorithm has been preliminarily validated, which is not the same as prospectively validated in an independent cohort.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for radiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free